mms mohamad zahreddine

As Chief Information and Technology Officer and a member of the Executive Team at MMS, Mohamad Zahreddine is responsible for overseeing the operational and strategic aspects of the company’s Technologies, Quality and Compliance, Business Process Transformation, Product Development, Information Security, and overall Governance. 

He has established governance over key enterprise business processes and led the formation and implementation of a holistic technology, governance, and compliance strategy. By leading quality and compliance and developing tech-enabled enterprise strategies, Mohamad’s role is integral in developing solutions for both internal and customer processes. He has expertise in global ERP implementations, manufacturing systems and processes, engineering systems, sales and operations, and information security, including technical and quality certifications. He is proficient and experienced at identifying emerging technology needs within the pharmaceutical industry, including regulatory requirements and IT controls to support clinical trial execution and transparency.

In the pharmaceutical industry, technological advancements are constantly evolving to effectively bring life-changing therapies to market. Change should be embraced, not feared, in all levels of business in order to move forward.
Mohamad Zahreddine
Chief Operating Officer

Mohamad brings a visionary approach with nearly 30 years of global experience in Business and Information Technology (IT), Global Enterprise Resource Planning (ERP), and a strong passion for digital transformation. Prior to MMS, he held several global leadership positions in the industry and led multiple IT and business systems transformation initiatives. Mohamad holds a Master of Science in Computer and Information Systems from the University of Detroit Mercy and a Bachelor’s degree in Computer Information Systems from the Detroit College of Business. He is also a member of the Forbes Technology Council.

Suggested For You

perspectives

November 21st, 2024

Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success

news

November 19th, 2024

MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year

perspectives

November 12th, 2024

REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar

news

November 8th, 2024

MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

perspectives

November 6th, 2024

How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure

perspectives

October 29th, 2024

Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies

perspectives

October 22nd, 2024

Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development

perspectives

October 15th, 2024

Putting the Action in Diversity Action Plans and the Real-Time Data Visualization Technology Needed to Ensure It Happens

news

October 15th, 2024

MMS Recognized with EcoVadis Bronze Medal for Leadership in ESG Sustainability Efforts as a Leading Clinical Research Organization (CRO)

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth